Real-World Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Two Belgian University Hospitals

被引：0
|
作者：
Jadot, Gaspard [1 ]
Depaus, Julien [2 ]
Vekemans, Marie-Christiane [2 ,3 ]
机构：
[1] Clin Univ St Luc, Brussels, Belgium
[2] Univ Catholic Louvain, Dept Haematol, CHU UCL Namur, Yvoir, Belgium
[3] Univ Catholic Louvain, UCLouvain, Brussels, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-032
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [21] Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience
    Ghamsari, Farid
    Trando, Aaron
    Medley, Katherine
    Martino, Janine
    Block, Shanna
    Doan, Thu
    Wells, Kaitlyn
    Quach, Anthony C.
    Cheng, Renee Gong
    Costello, Caitlin
    Jeong, Ah-Reum
    Saunders, Ila M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537
  • [23] Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeannene
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne
    BLOOD, 2018, 132
  • [24] Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma
    Tan, Carlyn
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Rajeeve, Sridevi
    Hashmi, Hamza
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Lesokhin, Alexander
    Korde, Neha
    Lin, Dee
    Wu, Bingcao
    Fowler, Jessica
    Fernandez, Mariana
    Kim, Nina
    Doyle, Margaret
    Hester, Laura
    Orozco, Jennifer
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S91 - S92
  • [25] Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Usmani, Saad Z.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (06)
  • [26] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    BLOOD, 2016, 128 (22)
  • [27] Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis
    Varma, Gaurav
    Fogel, Lindsay
    Gordon, Beth
    Saldarriaga, Mateo Mejia
    Ahn, Jaeil
    Aleman, Adolfo
    Caro, Jessica
    Rosenberg, Maya C.
    Monge, Jorge
    Parmar, Harsh
    Kaminetzky, David
    Moskovits, Tibor
    Siegel, David S.
    Morgan, Gareth J.
    Niesvizky, Ruben
    Davies, Faith E.
    Biran, Noa
    LEUKEMIA & LYMPHOMA, 2025,
  • [28] Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel M.
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew J.
    Sperling, Adam S.
    Anderson Jr, Larry D.
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [29] Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience
    Feixas, Pablo Tenorio
    Cox, Catrin
    Peer, Xavier
    Cuthill, Kirsty
    Benjamin, Reuben
    Gunawan, Arief
    Cuadrado, Maria
    de Farias, Madson Correia
    Jones, John
    Shin, Jin-Sup
    Batool, Asma
    Bowcock, Stella
    Omer, Musab
    Tawde, Prachi
    Bailey, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S92
  • [30] Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
    Cohen, Yael C.
    Magen, Hila
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Chu, Michael P.
    Rodriguez-Otero, Paula
    Avivi, Irit
    Quijano Carde, Natalia A.
    Kumar, Ashwini
    Krevvata, Maria
    Peterson, Michelle R.
    Di Scala, Lilla
    Scott, Emma
    Hilder, Brandi
    Vanak, Jill
    Banerjee, Arnob
    Oriol, Albert
    Morillo, Daniel
    Mateos, Maria-Victoria
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (02): : 138 - 149
12345